Last reviewed · How we verify
Gentamicins
Gentamicins, marketed by Lund University, is an established antibiotic with a key composition patent expiring in 2028. The drug's primary strength lies in its well-established market presence and long-term use in treating bacterial infections. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Gentamicins |
|---|---|
| Also known as | Prehabituation, PREHAB, Intratympanic installation of gentamicin |
| Sponsor | Lund University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Intra-nodal Injection of Gentamicin for the Treatment of Suppurated Cat Scratch Disease's Lymphadenitis (PHASE3)
- Prophylaxis Against Surgical Site Infections Using Local as Well as Systemic Antibiotic (NA)
- Prophylactic Antibiotic Coated Nail to Prevent Infection: A Clinical Trial (PHASE4)
- Aminoglycosides in Early Sepsis (PHASE4)
- Efficacy of Local Gentamicin Containing Collagen In Prevention of Post Stermotomy Infection In Cardiac Surgery (NA)
- Dual vs. Single-Antibiotic Impregnated Cement in Hemiarthroplasty for Femoral Neck Fracture (PHASE3)
- Extended Interval Dosing of Gentamicin in Neonates
- Multichannel Vestibular Implant Early Feasibility Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gentamicins CI brief — competitive landscape report
- Gentamicins updates RSS · CI watch RSS
- Lund University portfolio CI